Oncology - Urological
Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update
21 Feb, 2021 | 21:47h | UTC
Preliminary study suggests there may be a role for prostate cancer screening with magnetic resonance imaging
16 Feb, 2021 | 01:50h | UTCCommentaries: Short MRI Protocol Could Be Alternative for Prostate Cancer Follow-Up – Diagnostic Imaging AND Short MRI exam shows promise for prostate cancer screening follow-up – AuntMinnie (free registration required)
Commentary on Twitter
A handy infographic of our recently published research
Full paper is open access and free for all 🔬📜🙌
👉https://t.co/xDlz1A4kjR@eldredevans @JAMAOnc @EmilyD_stats @SageOfLondon1 @Connor_Urol @ImperialSandC @LondonProstate1 @Francy_lif @ProfPadhani @HemmySokhi pic.twitter.com/cEwSCv4NXy— Imperial Prostate (@IP_London) February 14, 2021
RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
15 Feb, 2021 | 00:36h | UTCLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival was significantly longer with lenvatinib plus pembrolizumab than with sunitinib.
— NEJM (@NEJM) February 13, 2021
RCT: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
15 Feb, 2021 | 00:34h | UTCEnfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma
15 Feb, 2021 | 00:32h | UTCA comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress
Long-term data: No difference in cardiovascular mortality or morbidity with transdermal estradiol vs. LHRH agonists for androgen suppression in prostate cancer
15 Feb, 2021 | 00:31h | UTCTransdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme – The Lancet (link to abstract – $ for full-text)
RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer
15 Feb, 2021 | 00:29h | UTC[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today
RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer
5 Feb, 2021 | 01:27h | UTCCommentary: Clinical trial: Using MRI for prostate cancer diagnosis equals or beats current standard – Ontario Institute for Cancer Research AND Another Win for MRI and Targeted Prostate Biopsy – MedPage Today (free registration required)
Related: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis – New England Journal of Medicine (study and commentaries) Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis – European Urology AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer (studies and commentaries)